Legislation


HB 2536 – Texas

Status: Enacted
Year Introduced: 2019
Link: https://capitol.texas.gov/tlodocs/86R/billtext/html/HB02536I.htm

Relating to transparency related to drug costs. HB 2536 requires a pharmaceutical drug manufacturer to submit a report to the executive commissioner of the Health and Human Services Commission (HHSC) stating the current wholesale acquisition cost information for the FDA-approved drugs sold in or into Texas by that manufacturer. The bill requires the executive commissioner to develop a website to provide to the general public the drug price information and requires that the website be made available on the HHSC website. The bill requires a pharmaceutical drug manufacturer to submit a report to the executive commissioner of HHSC not later than the 30th day after the effective date of an increase of 50 percent or more in wholesale acquisition cost of a drug with a wholesale acquisition cost of at least $100 for a 30-day supply. The bill requires each pharmacy benefit manager to file with the commissioner of insurance a report that states for the immediately preceding calendar year the aggregated rebates, fees, price protection payments, and other payments collected from pharmaceutical drug manufacturers and the aggregated dollar amount of those payments that were passed to health benefit plan issuers and to enrollees at the point of sale of a prescription drug. The bill requires a health benefit plan issuer to submit to the commissioner of insurance a report that contains specified information regarding prescription drugs across all plans, including certain information about spending and premium increases and specialty drug utilization management.


Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found